Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndromeCOVID-19 관련 사이토카인 방출 증후군 치료에서 IL-6 억제제의 역할Review Published on 2021-01-212022-09-12 Journal: International Journal of Medical Sciences [Category] 진단, [키워드] (Tocilizumab anti-IL-6 appear Case report classical coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patients CRS cytokine Cytokine release syndrome described effective Evidence evidence of feature IL-6 IL-6 inhibitor IL-6 inhibitors information inhibiting interleukin interleukin-6 interleukin-6 inhibitor. key factor Pathogenesis pathology patients with COVID-19 rationale role sarilumab severe coronavirus disease severe COVID-19 severe COVID-19 patient severe COVID-19 patients Signaling siltuximab syndrome Therapeutics Tocilizumab trans Treatment triggering [DOI] 10.7150/ijms.53564 PMC 바로가기 [Article Type] Review
Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-AnalysisSystematic Review Published on 2020-12-152022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] 95% CI Analysis analyzed anti-IL-6 anti-IL-6 signaling agents benefit blockade Clinical improvement clinical trial registry Control coronavirus disease COVID-19 COVID-19 case COVID-19 disease criteria Critical Critical disease current Cytokine storm detrimental driving Efficacy eligibility check Evidence evidence of ICU admission IL-6 IL-6 signaling infection risk inhibitor ISI mechanical ventilation Meta-analysis Mortality mortality rate Patient patients with COVID-19 reduce reduce mortality reduced review risk Secondary infection secondary infections Signaling significantly Standard of care Stata systematic review treated patient was performed Web of Science [DOI] 10.3389/fphar.2020.615972 PMC 바로가기 [Article Type] Systematic Review
Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review토실리주맙으로 치료한 코로나19 환자의 임상 결과: 개별 환자 데이터 체계적 검토Article Published on 2020-11-012022-09-12 Journal: Journal of medical virology [Category] 진단, [키워드] acute respiratory distress acute respiratory syndrome added analyzed anti-IL-6 anti-interleukin-6 receptor antibody average baseline baseline characteristics C-reactive protein (CRP Case report cause changes in Characteristics clinical Clinical outcome clinical outcomes Comorbidity coronavirus coronavirus disease COVID-19 COVID-19 patient CRP level current cytokine release storm Cytokine storm decrease demographics elevated Endpoint Evidence Fisher hospital hyperinflammatory state hypertension IL-6 IL-6 level IL-6 pathway in-hospital complications in-hospital mortality inclusion criteria individual level individual patient data inflammatory markers inhibition interleukin-6 interquartile range knowledge Laboratory male median nonsurvivor not significantly different observational study occurred outcome over pathway Patient patient data patients performed primary endpoint Primary outcome randomized control trial recent receptor reported SARS-CoV-2 secondary severe COVID-19 significantly significantly higher Standard deviation surviving patients survivor syndrome systematic review the primary endpoint therapy Tocilizumab treated Treatment worsened disease [DOI] 10.1002/jmv.26038 PMC 바로가기 [Article Type] Article
Immunomodulatory Therapies for COVID-19 in Solid Organ Transplant RecipientsCOVID19 and Transplantation (R Avery, Section Editor) Published on 2020-10-232022-10-31 Journal: Current Transplantation Reports [Category] COVID-19, [키워드] absence administration Anecdotal anti-IL-1 anti-IL-6 appear bacterial superinfection baseline benefit canakinumab Case series characterized clinical benefit clinical experience cohort study Colchicine control group coronavirus disease Corticosteroid COVID-19 CRS cytokine Cytokine release syndrome Deleterious Efficacy and safety Evidence finding heterogeneity Hyperinflammatory immunomodulation immunomodulatory therapy Immunosuppression inhibitor Interpretation kidney lack limit management monoclonal NLRP3 inflammasome non-transplant patients observational study Patient pleiotropic Pneumonia randomized clinical trial RCT recent recipient reported review Safe shown Solid solid organ transplantation SOT survival therapeutic strategy tissue damage Tocilizumab tocilizumab therapy Transplant with COVID-19 [DOI] 10.1007/s40472-020-00306-x PMC 바로가기 [Article Type] COVID19 and Transplantation (R Avery, Section Editor)
Use of Tocilizumab in COVID-19: A Systematic Review and Meta-Analysis of Current EvidenceInternal Medicine Published on 2020-10-092022-10-31 Journal: Cureus [Category] COVID-19, [키워드] 95% confidence interval Abstract analyses Analysis anti-IL-6 article articles baseline characteristics biologic agent calculated case-control study collaboration college control arm control group coronavirus disease COVID-19 COVID-19 patients Critical Critically ill current database demonstrated Denmark Efficacy elevated Endpoint Health IL-6 Immunological response Infection intensive care interleukin-6 invasive ventilation material mean difference Meta-analysis Mortality observational studies outcome oxygen saturation Patient patients with COVID-19 pharmacological treatment positive random effect model reducing mortality regimen reported Result review risk risk ratio Safe Safety SARS-CoV-2 searched Seven severe COVID-19 significant difference significantly lower standard care group Stata Corporation Station suggested systematic review Tocilizumab tocilizumab patient treatment with tocilizumab were used [DOI] 10.7759/cureus.10869 PMC 바로가기 [Article Type] Internal Medicine
Cytokine Storms in Cancer and COVID-19Article Published on 2020-10-022022-10-05 Journal: Cancer cell [Category] SARS, 신약개발, [키워드] anti-IL-6 Cancer clinical trials COVID-19 COVID-19 pandemic IL-6 immune response Infectious disease Research SARS-CoV-2 SARS-CoV-2 research storm [DOI] 10.1016/j.ccell.2020.09.019 [Article Type] Article
Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality사이토카인 방출 증후군: COVID-19 사망률을 줄이기 위한 솔루션으로 전염증성 사이토카인 억제Review Published on 2020-09-012022-09-12 Journal: European cytokine network [Category] SARS, 진단, [키워드] acute respiratory distress affected anti-IL-6 antibody cascade cause Corona Corona virus COVID-19 COVID-19 mortality critically ill patients CRS cytokine level cytokine release Cytokine release syndrome death disease elevated end organ explained IL-1 IL-6 mechanism of action occur pandemic Patient Potential pro-inflammatory cytokine pro-inflammatory cytokines proportion reached reduce mortality rate reducing Severe case Severe patient syndrome the disease Therapeutic approach TNF-alpha Treatment [DOI] 10.1684/ecn.2020.0451 PMC 바로가기 [Article Type] Review
Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With ObesityEndocrinology Published on 2020-07-282022-10-31 Journal: Frontiers in Endocrinology [Category] COVID-19, MERS, SARS, [키워드] ACE-2 ACE2 expression adipose Adipose tissue amplification anti-IL-6 Anti-inflammatory antibody Anticoagulant caused changes in characterized Clinical management Complication country COVID-19 COVID-19 hospitalization COVID-19 patient Cytokine storm death develop drug Drug discovery dysregulation form greater Hypercoagulopathy IL-1β IL-6 inhibition immune activation immunopathological individual Infection Inflammatory response lymphocyte lymphopenia mechanical ventilation morbidity and mortality obesity occur outcome Pneumonia Prevalence pro-inflammatory pro-inflammatory cytokine public health risk risk factor SARS-CoV-2 SARS-CoV-2 host cell SARS-COV-2 infection severe symptom susceptibility target the SARS-CoV-2 therapeutic effect therapeutic strategy tissue Treatment viral spread visceral [DOI] 10.3389/fendo.2020.00530 PMC 바로가기 [Article Type] Endocrinology
The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infectionReview Published on 2020-06-162022-11-01 Journal: Critical Care [Category] COVID-19, SARS, [키워드] ACE2 Activation angiotensin-converting enzyme 2 anti-IL-6 blockade Coagulation COVID-19 COVID-19 patient COVID-19 patients Cytokines D-dimer direct viral infection elevated endothelial Endothelial cell endothelial cells Endothelial dysfunction Endotheliitis evidenced explain histopathological identify IL-2 receptor IL-6 Immunomodulatory therapies immunothrombosis Infection infections Inflammation interleukin-6 leukocyte microcirculatory function organ organ dysfunction prevalent pro-inflammatory cytokine storm protease recruitment SARS-CoV-2 serine 2 severe SARS-CoV-2 target thrombosis Thrombotic events transmembrane Trial tumor necrosis factor-α Vascular vascular dysfunction venous [DOI] 10.1186/s13054-020-03062-7 PMC 바로가기 [Article Type] Review
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patientsViewpoint Published on 2020-06-112022-11-01 Journal: Critical Care [Category] COVID-19, SARS, [키워드] acute respiratory distress Admission anti-IL-6 anti-TNF approach approaches ARDS Care Complication condition COVID-19 COVID-19 patient Cytokine storm Cytokines detrimental effect drug Healthcare systems hospital immunomodulating drugs IMPROVE include increased mortality intensive care interleukin-6 Isolation JAK inhibitor Janus kinases molecular targeted therapy pharmacological Pneumonia Prognosis reducing SARS-CoV-2 syndrome therapeutic Therapeutic strategies tumor necrosis factor [DOI] 10.1186/s13054-020-03020-3 PMC 바로가기 [Article Type] Viewpoint